WO2014140374A3 - Anticorps monovalents anti-cd27 - Google Patents

Anticorps monovalents anti-cd27 Download PDF

Info

Publication number
WO2014140374A3
WO2014140374A3 PCT/EP2014/055331 EP2014055331W WO2014140374A3 WO 2014140374 A3 WO2014140374 A3 WO 2014140374A3 EP 2014055331 W EP2014055331 W EP 2014055331W WO 2014140374 A3 WO2014140374 A3 WO 2014140374A3
Authority
WO
WIPO (PCT)
Prior art keywords
monovalent antibody
monovalent
conjugate
fusion protein
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/055331
Other languages
English (en)
Other versions
WO2014140374A2 (fr
Inventor
Albrecht Gruhler
Peder Lisby NØRBY
Louise Hjerrild ZEUTHEN
Leif Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2014140374A2 publication Critical patent/WO2014140374A2/fr
Publication of WO2014140374A3 publication Critical patent/WO2014140374A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps monovalent, par exemple un fragment Fab, qui est capable de spécifiquement lier CD27 et réduire la signalisation induite par CD27. La présente invention concerne en outre une protéine de fusion ou un conjugué comprenant l'anticorps monovalent de l'invention et une fraction de prolongement de la demi-vie. L'anticorps monovalent, la protéine de fusion ou le conjugué de l'invention peuvent être adaptés à une utilisation en tant que médicament, par exemple dans le traitement de maladies auto-immunes dans lesquelles la suppression de la signalisation de CD27 est souhaitable.
PCT/EP2014/055331 2013-03-15 2014-03-17 Anticorps monovalents anti-cd27 Ceased WO2014140374A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361788554P 2013-03-15 2013-03-15
EP13159432.7 2013-03-15
US61/788,554 2013-03-15
EP13159432 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014140374A2 WO2014140374A2 (fr) 2014-09-18
WO2014140374A3 true WO2014140374A3 (fr) 2014-12-04

Family

ID=47877931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/055331 Ceased WO2014140374A2 (fr) 2013-03-15 2014-03-17 Anticorps monovalents anti-cd27

Country Status (1)

Country Link
WO (1) WO2014140374A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172260A1 (fr) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3790629A1 (fr) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Procédés et compositions pour le traitement du cancer
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (fr) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
WO2024091870A2 (fr) * 2022-10-24 2024-05-02 Phanes Therapeutics, Inc. Anticorps anti-egfrviii et leurs utilisations
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130434A2 (fr) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
WO2012004367A1 (fr) * 2010-07-09 2012-01-12 N.V. Organon Anticorps agoniste de cd27
WO2013138586A1 (fr) * 2012-03-15 2013-09-19 Janssen Biotech, Inc. Anticorps anti-cd27 humains, leurs procédés et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130434A2 (fr) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
WO2012004367A1 (fr) * 2010-07-09 2012-01-12 N.V. Organon Anticorps agoniste de cd27
WO2013138586A1 (fr) * 2012-03-15 2013-09-19 Janssen Biotech, Inc. Anticorps anti-cd27 humains, leurs procédés et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGEMATSU K ET AL: "B CELL SUBPOPULATIONS SEPARATED BY CD27 AND CRUCIAL COLLABORATION OF CD27+ B CELLS AND HELPER T CELLS IN IMMUNOGLOBULIN PRODUCTION", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, no. 8, 1 January 1997 (1997-01-01), WILEY - V C H VERLAG GMBH & CO. KGAA, DE, pages 2073 - 2079, XP001031448, ISSN: 0014-2980, DOI: 10.1002/EJI.1830270835 *
GREENALL SAMEER A ET AL: "Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.", PLOS ONE, vol. 7, no. 4, E34658, April 2012 (2012-04-01), pages 1 - 10, XP002697775, ISSN: 1932-6203 *
JEVSEVAR SIMONA ET AL: "PEGylation of antibody fragments for half-life extension", METHODS IN MOLECULAR BIOLOGY, vol. 901, 1 January 2012 (2012-01-01), (CLIFTON, N.J.) UNITED STATES, pages 233 - 246, XP009169915, ISSN: 1940-6029 *
KOBATA T ET AL: "CD27-CD70 interactions regulate B-cell activation by T cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, no. 24, 21 November 1995 (1995-11-21), NATIONAL ACADEMY OF SCIENCES, US, pages 11249 - 11253, XP002582843, ISSN: 0027-8424, DOI: 10.1073/PNAS.92.24.11249 *
MAGE R G ET AL: "B cell and antibody repertoire development in rabbits: The requirement of gut-associated lymphoid tissues", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS, US, vol. 30, no. 1-2, 1 January 2006 (2006-01-01), pages 137 - 153, XP027942078, ISSN: 0145-305X, [retrieved on 20060101] *
MATTHIAS MATTER ET AL: "Elimination of chronic viral infection by blocking CD27 signaling", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 203, no. 9, 21 August 2006 (2006-08-21), ROCKEFELLER UNIVERSITY PRESS, US, pages 2145 - 2155, XP007906013, ISSN: 0022-1007, DOI: 10.1084/JEM.20060651 *
NAKAJIMA A ET AL: "Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY, vol. 109, no. 2, 22 September 2000 (2000-09-22), ELSEVIER SCIENCE PUBLISHERS BV, pages 188 - 196, XP002423716, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(00)00324-6 *

Also Published As

Publication number Publication date
WO2014140374A2 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
HK1252666A1 (zh) 针对cd40的抗体
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2019011952A (es) Proteina anti-garp y sus usos.
WO2011113019A3 (fr) Protéines ctla4 et leurs utilisations
WO2012017324A3 (fr) Composition pharmaceutique à combinaison et méthodes de traitement de maladies ou états associés à des maladies neurodégénératives
WO2014150877A3 (fr) Anticorps anti-tau et leurs procédés d'utilisation
WO2014197849A3 (fr) Anticorps anti-c10orf54 et leurs utilisations
HK1252863A1 (zh) 结合cd22的抗体分子
HK1219983A1 (zh) 治疗性肽
WO2013072813A3 (fr) Peptides cytotoxiques et conjugués anticorps-médicaments de ceux-ci
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
WO2014189973A3 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
WO2014145159A3 (fr) Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
WO2014151680A8 (fr) Traitement et prévention d'une lésion rénale aiguë à l'aide d'anticorps anti- αvβ5
WO2015007536A3 (fr) Fusokines impliquant des cytokines ayant des affinités de liaison à leurs récepteurs fortement réduites
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
MX2015011199A (es) Agentes terapéuticos de csf1.
WO2014163714A3 (fr) Conjugués médicament-anticorps
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX2016001145A (es) Proteina de fusion terapeutica.
WO2013149111A3 (fr) Anticorps anti-tlr4 et utilisations de ceux-ci
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2012006341A8 (fr) Anticorps anti-ron
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
CA2866232A1 (fr) Composition pharmaceutique aqueuse contenant un agent therapeutique biologique et de la guanidine ou un derive de guanidine, et injection comprenant la composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710326

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14710326

Country of ref document: EP

Kind code of ref document: A2